Efficacy and Safety of Sparsentan (RE-021), A Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): A Randomized, Double-blind, Active-Control, Dose-Escalation Study
A study for patients with Focal Segmental Glomerulosclerosis (FSGS) using study drug Sparsentan
Sponsor: Retrophin Inc
Enrolling: Male and Female Patients
IRB Number: AAAP8766
U.S. Govt. ID: NCT01613118
Contact: Jai Radhakrishnan: (212) 305-3273 / jr55@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the safety and effectiveness of an investigational medication in patients with focal segmental glomerulosclerosis (FSGS). The goal is to learn whether the investigational medication may change the amount of protein in the urine and decrease proteinuria.
This study is closed
Investigator
Jai Radhakrishnan, MD
Do You Qualify?
Do you have a confirmed diagnosis of focal segmental glomerulosclerosis (FSGS)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Jai Radhakrishnan
jr55@cumc.columbia.edu
(212) 305-3273
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE